Vistagen Therapeutics Inc (NASDAQ:VTGN) – Stock analysts at Oppenheimer reduced their Q3 2019 earnings per share estimates for Vistagen Therapeutics in a report issued on Sunday, November 4th. Oppenheimer analyst J. Olson now expects that the company will post earnings of ($0.30) per share for the quarter, down from their prior estimate of ($0.19). Oppenheimer has a “Buy” rating and a $6.00 price objective on the stock. Oppenheimer also issued estimates for Vistagen Therapeutics’ Q4 2019 earnings at ($0.30) EPS, FY2019 earnings at ($1.10) EPS, FY2020 earnings at ($1.48) EPS, FY2021 earnings at ($1.76) EPS, FY2022 earnings at ($2.02) EPS and FY2023 earnings at ($2.68) EPS.
Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Monday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.13).
Shares of VTGN opened at $2.10 on Wednesday. Vistagen Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $2.65. The company has a market capitalization of $65.22 million, a PE ratio of -1.89 and a beta of -1.53.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Featured Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.